| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
13-Methyltetradecanoic acid (13-MTD; 0-140 μg/mL; 12-24 hours) induces apoptosis in human bladder cancer cells, inhibiting their viability and growth [1]. When cells were treated with 70 μg/mL with 13-methyltetradecanoic acid (13-MTD) for two to four days, there was a notable increase in the amount of sub-G1 DNA content in a time-dependent manner. Within 48 hours, the proportion of sub-G1 DNA content increased from 9.25% to 85.3%[1]. Lowering Bcl-2 and increasing Bax, 13-Methyltetradecanoic acid (13-MTD; 70 μg/mL; 2–24 hours) does both. This encourages malfunction of the mitochondria, which releases cytochrome c into the cytoplasm and triggers the proteolytic activation of caspases. 13-Methyltetradecanoic acid stimulates the phosphorylation of p38 and c-Jun N-terminal kinase (JNK) while downregulating the phosphorylation of AKT [1].
|
|---|---|
| ln Vivo |
In xenograft models, 13-Methyltetradecanoic acid (13-MTD; 70 mg/kg/day; oral gavage; daily; for 30 days) suppresses tumor growth considerably [2].
|
| Cell Assay |
Cell viability assay[1]
Cell Types: Bladder cancer cell lines T24, 5637 and UM-UC-3 Tested Concentrations: 0 μg/mL, 35 μg/mL, 70 μg/mL, 105 μg/mL and 140 μg/mL Incubation Duration: 12 hrs (hours), 24 hrs (hours) Experimental Results: Inhibited cell viability in a dose- and time-dependent manner. Cell cycle analysis[1] Cell Types: Bladder cancer cell lines T24, 5637 and UM-UC-3 Tested Concentrations: 70 μg/mL Incubation Duration: 2 hrs (hours), 8 hrs (hours), 24 hrs (hours) or 48 hrs (hours) Experimental Results: Result in significant accumulation with sub- G1 DNA content of cells in a time-dependent manner. Western Blot Analysis[1] Cell Types: T24, 5637 and UM-UC-3 Cell Tested Concentrations: 70 μg/mL Incubation Duration: 2 hrs (hours), 8 hrs (hours), 24 hrs (hours) Experimental Results: Bcl-2 down-regulated and Bax up-regulated, and AKT phosphate down-regulated Phosphorylate and activate p38 and c-Jun N-terminal kinase (JNK) phosphorylation. |
| Animal Protocol |
Animal/Disease Models: BALB/C nude mice injected with Jurkat lymphoma cells [2]
Doses: 70 mg/kg/day Route of Administration: po (oral gavage); daily; 30-day Experimental Results: Effectively inhibited the growth of xenograft models in vivo. |
| References |
|
| Additional Infomation |
Isopentadecanoic acid is a branched-chain saturated fatty acid comprising tetradecanoic (myristic) acid substituted at position 13 by a methyl group. It is a long-chain fatty acid, a branched-chain saturated fatty acid and a methyl-branched fatty acid. It is a conjugate acid of an isopentadecanoate.
13-Methyltetradecanoic acid has been reported in Streptomyces manipurensis, Chondrosia reniformis, and other organisms with data available. 13-Methyltetradecanoic Acid is a branched-chain saturated fatty acid that is comprised of tetradecanoic acid with a methyl group on the carbon in the thirteenth position. |
| Molecular Formula |
C15H30O2
|
|---|---|
| Molecular Weight |
242.3975
|
| Exact Mass |
242.225
|
| CAS # |
2485-71-4
|
| PubChem CID |
151014
|
| Appearance |
White to off-white solid powder
|
| Density |
0.894 g/cm3
|
| Boiling Point |
355.5ºC at 760 mmHg
|
| Flash Point |
197.4ºC
|
| Vapour Pressure |
5.19E-06mmHg at 25°C
|
| Index of Refraction |
1.451
|
| LogP |
5.018
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
17
|
| Complexity |
176
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZOCYQVNGROEVLU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H30O2/c1-14(2)12-10-8-6-4-3-5-7-9-11-13-15(16)17/h14H,3-13H2,1-2H3,(H,16,17)
|
| Chemical Name |
13-methyltetradecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1254 mL | 20.6271 mL | 41.2541 mL | |
| 5 mM | 0.8251 mL | 4.1254 mL | 8.2508 mL | |
| 10 mM | 0.4125 mL | 2.0627 mL | 4.1254 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
